Browsing ODA Open Digital Archive by Author "Garred, Øystein"

Now showing items 1-4 of 4

    • Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials 

      Andresen, Nikolai Kragøe; Røssevold, Andreas Hagen; Borgen, Elin; Schirmer, Cecilie; Gilje, Bjørnar; Garred, Øystein; Lømo, Jon; Stensland, Marius; Nordgård, Oddmund; Falk, Ragnhild Sørum; Ruud, Randi Margit; Russnes, Hege Elisabeth Giercksky; Kyte, Jon A; Naume, Bjørn (Peer reviewed; Journal article, 2024)
      Immune checkpoint inhibitors (ICIs) have been introduced in breast cancer (BC) treatment and better biomarkers are needed to predict benefit. Circulating tumor cells (CTCs) are prognostic in BC, but knowledge is limited ...

    • Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: A randomized phase 2b trial 

      Andresen, Nikolai Kragøe; Røssevold, Andreas Hagen; Quaghebeur, Claire; Gilje, Bjørnar; Boge, Beate; Gombos, Andrea; Falk, Ragnhild Sørum; Ruud, Randi Margit; Julsrud, Lars; Garred, Øystein; Russnes, Hege Elisabeth Giercksky; Lereim, Ragnhild Reehorst; Chauhan, Sudhir Kumar; Lingjærde, Ole Christian; Dunn, Claire; Naume, Bjørn; Kyte, Jon A (Peer reviewed; Journal article, 2024)
      Background Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR+ mBC). Doxorubicin and low- dose cyclophosphamide are reported to induce immune ...

    • LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer 

      Sas-Chen, Aldema; Aure, Miriam Ragle; Leibovich, Limor; Carvalho, Silvia; Enuka, Yehoshua; Körner, Cindy; Polycarpou-Schwarz, Maria; Lavi, Sara; Nevo, Nava; Kuznetsov, Yuri; Yuan, Justin; Azuaje, Francisco; Ulitsky, Igor; Diederichs, Sven; Wiemann, Stefan; Yakhini, Zohar; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Yarden, Yosef; Sauer, Torill; Geisler, Jürgen; Hofvind, Solveig; Bathen, Tone Frost; Borgen, Elin; Engebråten, Olav; Fodstad, Øystein; Garred, Øystein; Geitvik, Gry; Kåresen, Rolf; Naume, Bjørn; Mælandsmo, Gunhild; Russnes, Hege Elisabeth Giercksky; Schlichting, Ellen; Sørlie, Therese; Lingjærde, Ole Christian; Sahlberg, Kristine Kleivi; Skjerven, Helle; Fritzman, Britt (Journal article; Peer reviewed, 2016)
      Long noncoding RNAs (lncRNAs) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lncRNAs have been implicated in progression of specific subtypes of breast cancer. One aggressive, ...

    • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 

      Møller, Elen Kristine; Nord, Silje; Wedge, David C.; Lingjærde, Ole Christian; Silwal-Pandit, Laxmi; Gythfeldt, Hedda; Vollan, Hans Kristian Moen; Fleischer, Thomas; Krohn, Marit; Schlichting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit Muri; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebråten, Olav; Kristensen, Vessela N. (Genome medicine;10(1), Journal article; Peer reviewed, 2018-11-29)
      Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...